Mechanism
Abaloparatide is a 34-amino-acid synthetic analog of PTHrP (parathyroid hormone-related protein). The first 22 amino acids are identical to PTHrP; the C-terminal portion is engineered for selective binding to the PTH1 receptor’s RG conformation (transient activation, anabolic effect) over the R0 conformation (sustained activation, calcium-mobilizing effect).
PTH1 receptor activation has biphasic effects on bone:
- Intermittent (daily injection): primarily anabolic — stimulates osteoblast activity, increases bone formation rate, increases trabecular bone density
- Continuous (chronic high-level exposure, as in primary hyperparathyroidism): primarily catabolic — bone resorption increases, bone density decreases
The intermittent dosing of abaloparatide and teriparatide exploits the anabolic side. Abaloparatide’s selective binding to the RG conformation produces somewhat shorter receptor activation per dose, which appears to skew the anabolic-to-resorptive ratio further in the anabolic direction versus teriparatide.
Half-life is approximately 1.7 hours subcutaneously — short enough that each daily dose is a discrete pulse rather than chronic exposure.
What the evidence shows
Phase 3 ACTIVE trial (Miller PD et al, JAMA 2016): 2,463 postmenopausal women with osteoporosis randomized to abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo for 18 months.
Results at 18 months:
– New vertebral fractures: 0.6% abaloparatide, 0.8% teriparatide, 4.2% placebo
– Non-vertebral fractures: 2.7% abaloparatide vs 4.7% placebo (significant)
– Bone mineral density (lumbar spine): +9.2% abaloparatide vs +0.5% placebo
– Bone mineral density (total hip): +3.4% abaloparatide vs −0.1% placebo
ACTIVExtend (post-trial extension): Patients who received abaloparatide for 18 months were transitioned to alendronate (a bisphosphonate); the gains were preserved over 24 additional months.
Versus teriparatide: Head-to-head ACTIVE comparison showed abaloparatide non-inferior on vertebral fracture reduction with somewhat faster BMD gains and slightly lower hypercalcemia rates. The two drugs are similar in clinical effect; abaloparatide’s main differentiation is the auto-injector convenience and the biochemical profile.
Dosing literature
Approved dosing (subcutaneous, once daily):
- 80 mcg/day subcutaneous, abdominal injection via auto-injector (Tymlos pen)
- Maximum lifetime exposure: 18 months total
- Followed by transition to an antiresorptive agent (bisphosphonate, denosumab) to maintain the gained bone density
The 18-month cap is a class effect with PTH-pathway anabolics, originally driven by rat osteosarcoma signal in chronic high-dose preclinical studies. The signal hasn’t been observed in human clinical use, but the conservative cap remains in the FDA labeling.
Risks and adverse events
Common:
- Hypercalcemia, mild — typically asymptomatic, requires periodic calcium monitoring
- Hypercalciuria, with associated risk of nephrolithiasis
- Orthostatic hypotension (especially in first 4 hours post-dose)
- Injection site reactions
- Nausea, dizziness, headache
- Palpitations
Less common but important:
- Symptomatic hypotension or syncope post-injection — patients are counseled to inject in a position where falling won’t cause injury
- Hypercalcemia requiring dose modification
- Allergic reactions
Boxed warning (FDA): Risk of osteosarcoma based on rat preclinical data. Not observed in humans during the development program or post-marketing. Contraindicated in patients with elevated osteosarcoma risk (Paget’s disease of bone, prior skeletal radiation, unexplained alkaline phosphatase elevation, open epiphyses).
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Approved (Tymlos) | For postmenopausal osteoporosis at high fracture risk; men with osteoporosis added 2022. |
| European Union | Approved (Eladynos) | Same indication. |
| United Kingdom | Approved | NHS access criteria apply. |
| Japan | Approved | |
| Canada | Approved |
Manufacturer: Radius Health. List price ~$2,200/month US; access typically requires prior authorization for high-fracture-risk patients failing first-line therapy.
Where to get it
Through an endocrinologist, rheumatologist, or osteoporosis-specializing primary care clinician. Insurance coverage typically requires documentation of high fracture risk and bisphosphonate failure or intolerance.
We have no fulfillment partner for abaloparatide. (See How we make money.)
References (selected)
- Miller PD et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 2016 (ACTIVE). PubMed
- Cosman F et al. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc 2017.
Quick Facts
| Also Known As | BA-058, BIM-44058, PTHrP (1-34) analog |
|---|---|
| Sequence | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA |
| Molecular Formula | C174H300N56O49 |
| Molecular Weight | 3961 Da |
| PubChem CID | 76943386 |
Research Parameters
| Half-Life | ~1.7 hours (subcutaneous administration) |
|---|---|
| Stability | The commercial product (Tymlos) is provided as a sterile, preservative-free solution in a prefilled pen. Unopened pens should be stored refrigerated. Once in use, the pen can be stored at room temperature for up to 30 days. Stability data for lyophilized research-grade material is not standardized and depends on formulation. |
| Solubility | The commercial formulation is a ready-to-use solution. For research-grade lyophilized powder, reconstitution is typically performed with sterile water for injection or bacteriostatic water, following specific manufacturer or protocol guidelines. |
| Storage (Lyophilized) | For research-grade lyophilized powder: Store at -20°C or below, protected from light and moisture. Stable for up to 24 months when stored properly. |
| Storage (Reconstituted) | For research solutions after reconstitution: Store at 2-8°C (refrigerated) and use within a timeframe specified by the manufacturer or protocol, typically 24-48 hours unless bacteriostatic water is used, which may extend stability. Do not freeze. |
| Typical Research Dose | 80 mcg |
| Cycle Parameters | In clinical research for osteoporosis: Daily subcutaneous injection for a treatment period of up to 18-24 months. The total duration of therapy is limited to 2 years lifetime due to the osteosarcoma boxed warning. |
| Amino Acid Count | 34 |
Mechanism of Action
Abaloparatide acts as a selective agonist for the parathyroid hormone 1 receptor (PTH1R), a G-protein coupled receptor highly expressed on osteoblasts and osteocytes. Its mechanism is characterized by preferential activation of the Gαs/cAMP/PKA signaling pathway over the Gαq/PLC/PKC pathway compared to teriparatide (PTH 1-34). This selective signaling profile is believed to drive a more pronounced anabolic bone response with a transient effect on bone resorption.
PTH1R Activation and cAMP Signaling: Abaloparatide binds to PTH1R with high affinity, inducing a conformational state that strongly activates Gαs. This leads to increased adenylate cyclase activity, elevated intracellular cyclic AMP (cAMP), and activation of protein kinase A (PKA). In osteoblasts, this cascade promotes the expression of key anabolic genes like Runx2 and IGF-1, stimulating osteoblast differentiation, activity, and survival.
Wnt/β-catenin Pathway Modulation: The cAMP/PKA signaling induced by abaloparatide can inhibit glycogen synthase kinase-3β (GSK-3β), leading to stabilization and nuclear translocation of β-catenin. This activates Wnt-responsive genes critical for osteoblastogenesis and bone formation.
Transient RANKL Induction: Unlike continuous PTH exposure, the transient activation pattern of abaloparatide leads to a shorter, less pronounced increase in RANKL expression on osteoblasts. This results in a milder and briefer stimulation of osteoclast differentiation and bone resorption, favoring a net anabolic window where bone formation exceeds resorption.
Minimal Hypercalcemic Effect: The selective signaling, with relatively weaker activation of the Gαq/PLC pathway linked to calcium mobilization from bone and kidneys, contributes to a lower incidence and magnitude of hypercalcemia compared to teriparatide.
Research Applications
Osteoporosis and Bone Disorders: Abaloparatide has been extensively researched for the treatment of postmenopausal osteoporosis. Clinical trials demonstrate its efficacy in significantly increasing bone mineral density (BMD) at the lumbar spine and hip, and reducing the risk of vertebral and nonvertebral fractures. Its anabolic action stimulates new bone formation, improving bone microarchitecture and strength.
Fracture Healing: Preclinical research in animal models of fracture suggests that abaloparatide may accelerate fracture repair and callus formation. Studies indicate it can enhance the mechanical strength of healing bone, potentially offering a therapeutic avenue for difficult-to-heal fractures or non-unions.
Glucocorticoid-Induced Osteoporosis (GIOP): Research has explored its potential in preventing or treating bone loss associated with long-term glucocorticoid use. Its anabolic mechanism may be particularly suited to counteract the suppressed bone formation characteristic of GIOP.
Other Metabolic Bone Diseases: Preliminary investigations have examined its utility in conditions like osteogenesis imperfecta and male osteoporosis, though research is less extensive. The fundamental anabolic action on bone makes it a candidate for various states of low bone turnover.
Safety & Side Effects
In clinical trials, the most common adverse reactions were hypercalcemia, injection site reactions (erythema, pain, swelling), dizziness, nausea, headache, and palpitations. Hypercalcemia was typically mild, transient, and more common than with placebo but less frequent and severe than with teriparatide. An increased heart rate and orthostatic hypotension were observed more frequently than with placebo. There is a theoretical concern, based on rodent toxicology studies, of a potential risk for osteosarcoma with long-term use; however, no such signal has been observed in human studies to date. This risk is noted in a boxed warning. Anecdotal reports from clinical use are consistent with the trial safety profile.
Dosage Information
Disclaimer: The following information is derived from published clinical research and is presented for educational purposes only. Abaloparatide is a prescription drug, and its use must be supervised by a qualified healthcare professional.
In the pivotal clinical trial (ACTIVE), the approved and researched subcutaneous dose is 80 mcg administered once daily. The injection is typically given in the periumbilical region of the abdomen. The treatment duration in clinical studies has been up to 18 months for the primary fracture outcome, with longer extensions studied. Administration is recommended at a consistent time each day, independent of meals.
References
Miller, P.D., Hattersley, G., Riis, B.J., et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016;316(7):722–733.
Leder, B.Z., O'Dea, L.S., Zanchetta, J.R., et al. Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697–706.
Hattersley, G., Dean, T., Corbin, B.A., Bahar, H., Gardella, T.J. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2016;157(1):141–149.
Cosman, F., Miller, P.D., Williams, G.C., et al. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017;92(2):200–210.
Tella, S.H., & Gallagher, J.C. Prevention and Treatment of Postmenopausal Osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–170.
Dobnig, H., & Turner, R.T. The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1-34) on Bone Histomorphometry and Serum Chemistry in Rats. Endocrinology. 1997;138(11):4607–4612.